Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × radium Ra 223 dichloride × 30 days × Clear all

Phase

Phase 2 3 Phase 1/2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 78 Carboplatin 64 Cisplatin 60 Paclitaxel 50 Specimen Handling 49 Magnetic Resonance Spectroscopy 48 Gemcitabine 45 Docetaxel 34 Cyclophosphamide 34 Pemetrexed 31 Dexamethasone 30 Fluorouracil 29 Doxorubicin 29 Bevacizumab 29 Capecitabine 27 Radiotherapy 26 Oxaliplatin 26 durvalumab 25 Leucovorin 24 Rituximab 23 Radiation 23 Vincristine 22 Lenalidomide 21 Irinotecan 18 130-nm albumin-bound paclitaxel 18 Prednisone 17 Nivolumab 17 venetoclax 16 Letrozole 16 atezolizumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡